1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
CardioGenics Holdings Inc

CardioGenics Holdings Inc

CGNH
CardioGenics Holdings IncUS flagOther OTC
0.00
USD
- -
- -
12,000.00Market Cap
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
0.1
0.06
0.05
0.04
0.04
0.03
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.68
-0.47
-0.42
-0.85
-2.53
-0.5
-0.95
-0.04
-0.11
-0.02
-0.05
-0.04
-0.02
-0.01
Free Cash Flow per Basic Share
-0.6
-0.41
-0.35
-0.52
-0.1
-0.23
-0.02
-0.04
-0.03
-0.02
-0.01
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-10.91
-10.1
-10.12
-11.35
-13.01
-11.11
-1.09
-0.71
-0.75
-0.76
-0.79
-0.77
-0.52
-0.49
Tangible Book Value per Share
-0.02
0.09
-0.3
-1.05
-3.15
0.02
0.06
0.03
0.01
-0.01
-0.02
-0.02
-0.02
-0.02
Basic Weighted Avg Shares
4
4
4
4
5
6
30
50
54
56
57
62
94
101
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-658.21
-783.59
-710.04
-1,408.18
-846.53
-1,002.15
- -
- -
-63,040.75
-99,368.08
- -
- -
- -
- -
Depreciation Expense
1
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-2
-2
-4
-12
-3
-29
-2
-6
-1
-3
-3
-2
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-668.27
-791.94
-788.3
-2,181.78
-5,792.41
-1,599.39
- -
- -
-64,495.45
-100,851.89
- -
- -
- -
- -
Working Capital
- -
- -
1
-3
-12
- -
2
2
- -
-1
-1
-1
-2
-2
LT Debt
- -
- -
2
2
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
-1
-4
-15
- -
2
2
1
-1
-1
-1
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.72
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jul'15
Oct'15
Jan'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
92
93
Market Capitalization
3
4
3

Working Capital

FRC

•

in mil. unless spec.
Jul'15
Oct'15
Jan'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
205.94%
-24.64%
35.32%
Free Cash Flow
19.07%
-21.69%
1.94%
Net Income, GAAP
125.35%
38.42%
-28.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.01
-0.01
-0.01
- -
-0.04
2015
-0.01
- -
-0.01
- -
-0.02
2016
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Yahia Abdul Gawad
Full Time Employees
4
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
6295 Northam Drive Mississauga ON Canada L4V 1W8
IPO Date
Jun 9, 2004
Website
cardiogenics.com
Similar Companies
Genetic Signatures Limited (GSS.AX)
IDL Diagnostics AB (publ) (IDLDX.ST)
Proteome Sciences plc (PMSNF)
Diaceutics PLC (DXRX.L)
GRAIL, Inc. (GRAL)
LumiraDx Limited (LMDXW)
Business
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products targeting the immunoassay segment of the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally; its core offerings include the QL Care Analyzer, a portable, stand-alone, automated point-of-care immunoassay analyzer utilizing proprietary self-metering cartridges for on-site testing; a series of immunoassay tests designed to identify cardiac markers in blood during heart attacks; and paramagnetic beads serving as solid surfaces for heterogeneous immunoassay tests employed by clinical and research laboratories. Founded in 1997 and headquartered at 6295 Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8, Canada, the company, led by Founder, CEO and Director Dr. Yahia Gawad, focuses on innovative, cost-effective, patent-protected technologies to enhance healthcare professionals' diagnostic capabilities and patient management while reducing costs. Originally known as Jag Media Holdings Inc., it changed its name to CardioGenics Holdings Inc. in 2009; among its earlier strategic moves, it entered an asset purchase agreement in November 2015 to acquire substantially all assets of Ontario-based Plasticap, including manufacturing expertise for plastics to support production of its QL Care Analyzer cartridges and expansion into healthcare plastics, while maintaining Plasticap's client base, with related real property transactions finalized separately.

Company News

APIChat

  • defenseworld.net

    CardioGenics (OTCMKTS:CGNH) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

  • defenseworld.net

    CardioGenics (OTCMKTS:CGNH) & Avanos Medical (NYSE:AVNS) Financial Review

  • defenseworld.net

    CardioGenics (OTCMKTS:CGNH) Share Price Passes Above 200-Day Moving Average – Here’s Why

  • defenseworld.net

    Comparing CardioGenics (OTCMKTS:CGNH) & LENSAR (NASDAQ:LNSR)

  • defenseworld.net

    Contrasting DarioHealth (NASDAQ:DRIO) and CardioGenics (OTCMKTS:CGNH)

  • defenseworld.net

    Head-To-Head Analysis: IDEXX Laboratories (NASDAQ:IDXX) vs. CardioGenics (OTCMKTS:CGNH)

  • thelincolnianonline.com

    Head-To-Head Contrast: CardioGenics (OTCMKTS:CGNH) versus Nielsen (OTCMKTS:NLSN)